EARS vs. VINC, AVTX, TLPH, NRSN, ORGS, INDP, GLTO, APM, NERV, and KALA
Should you be buying Auris Medical stock or one of its competitors? The main competitors of Auris Medical include Vincerx Pharma (VINC), Avalo Therapeutics (AVTX), Talphera (TLPH), NeuroSense Therapeutics (NRSN), Orgenesis (ORGS), Indaptus Therapeutics (INDP), Galecto (GLTO), Aptorum Group (APM), Minerva Neurosciences (NERV), and KALA BIO (KALA). These companies are all part of the "medical" sector.
Auris Medical (NASDAQ:EARS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.
Auris Medical has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.
Auris Medical's return on equity of 0.00% beat Vincerx Pharma's return on equity.
6.0% of Auris Medical shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 22.9% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Vincerx Pharma had 1 more articles in the media than Auris Medical. MarketBeat recorded 3 mentions for Vincerx Pharma and 2 mentions for Auris Medical. Auris Medical's average media sentiment score of 0.05 beat Vincerx Pharma's score of 0.02 indicating that Auris Medical is being referred to more favorably in the media.
Vincerx Pharma has a consensus target price of $5.00, suggesting a potential upside of 437.63%. Given Vincerx Pharma's higher probable upside, analysts plainly believe Vincerx Pharma is more favorable than Auris Medical.
Auris Medical received 397 more outperform votes than Vincerx Pharma when rated by MarketBeat users. However, 64.52% of users gave Vincerx Pharma an outperform vote while only 57.60% of users gave Auris Medical an outperform vote.
Summary
Vincerx Pharma beats Auris Medical on 7 of the 12 factors compared between the two stocks.
Get Auris Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Auris Medical Competitors List
Related Companies and Tools
